Drugs for Spasticity (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 153)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Memantine |
Approved, Investigational |
Phase 4 |
|
41100-52-1, 19982-08-2 |
4054 |
Synonyms:
1,3-Dimethyl-5-adamantanamine
1,3-Dimethyl-5-aminoadamantane
1,3-DIMETHYLAMINOADAMANTANE
1-Amino-3,5-dimethyladamantane
3,5-Dimethyl-1-adamantanamine
3,5-Dimethyl-1-aminoadamantane
3,5-Dimethyltricyclo(3.3.1.1(3,7))decan-1-amine
AKATINOL
Axura
Axura®|Ebixa®|Namenda®
D-145
DMAA
DRG-0267
Ebixa
Exiba
FP-01
Lundbeck brand OF memantine hydrochloride
|
MARIXINO
Memantin
Memantina
Memantina [INN-Spanish]
MEMANTINE
Memantine [INN]
MEMANTINE HCL
Memantine hydrochloride
Memantinum
Memantinum [INN-Latin]
Merz brand OF memantine hydrochloride
Namenda
NAMENDA XR
NEMDATINE
NSC-102290
SUN-Y7017
VALIOS
|
|
2 |
|
Dopamine |
Approved |
Phase 4 |
|
62-31-7, 51-61-6 |
681 |
Synonyms:
2-(3,4-Dihydroxyphenyl)ethylamine
3,4 Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenylethylamine
3-Hydroxytyramine
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)-pyrocatechol
4-(2-AZANYLETHYL)BENZENE-1,2-DIOL
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL-279
CARBILEV
Deoxyepinephrine
Dopamin
Dopamina
DOPAMINE
DOPAMINE HCL
|
Dopamine hydrochloride
DOPAMIN-NATTERMAN
Dopaminum
Dopastat
Dophamine
DOPMIN
Dynatra
Hydrochloride, dopamine
Hydroxytyramin
Hydroxytyramine
Intropin
Medopa
NSC-169105
NSC-173182
Oxytyramine
PARCOPA
Revivan
SABAX DOPAMIN
SELECTAJET
SINEMET
|
|
3 |
|
GABA Agonists |
|
Phase 4 |
|
|
|
4 |
|
Dopamine Agents |
|
Phase 4 |
|
|
|
5 |
|
Antiparkinson Agents |
|
Phase 4 |
|
|
|
6 |
|
Excitatory Amino Acid Antagonists |
|
Phase 4 |
|
|
|
7 |
|
Dalfampridine |
Approved |
Phase 3 |
|
504-24-5 |
1727 |
Synonyms:
4-AMINOPYRIDINE
4-aminopyridine|4-AP|Ampyra®|EL-970
4-AP
4-PYRIDINAMINE
4-PYRIDYLAMINE
AMPYRA
AMPYRA EXTENDED RELEASE
AVITROL
DALFAMPRIDINE
EL-970
FAMPRIDINA
|
FAMPRIDINE
FAMPRIDINE-SR
FAMPRIDINUM
FAMPYRA
GAMMA-AMINOPYRIDINE
N07XX07
NEURELAN
NSC-15041
P-AMINOPYRIDINE
γ-Aminopyridine
|
|
8 |
|
Baclofen |
Approved |
Phase 3 |
|
1134-47-0 |
2284 |
Synonyms:
(+-)-Baclofen
4-Amino-3-(4-chlorophenyl)butyrate
4-Amino-3-(4-chlorophenyl)butyric acid
Alphapharm brand OF baclofen
apo Baclofen
apo-Baclofen
ApoBaclofen
Apotex brand OF baclofen
Ashbourne brand OF baclofen
ASTA medica brand OF baclofen
Athena brand OF baclofen
Atrofen
AWD, baclofen
b-(4-Chlorophenyl)gaba
b-(Aminomethyl)-4-chlorobenzenepropanoate
b-(Aminomethyl)-4-chlorobenzenepropanoic acid
b-(Aminomethyl)-p-chlorohydrocinnamate
b-(Aminomethyl)-p-chlorohydrocinnamic acid
b-(p-Chlorophenyl)-g-aminobutyrate
b-(p-Chlorophenyl)-g-aminobutyric acid
BA-34647
BACLOFEN
Baclofen alphapharm brand
Baclofen apotex brand
Baclofen ashbourne brand
Baclofen athena brand
Baclofen awd
Baclofen ciba-geigy brand
Baclofen irex brand
Baclofen isis brand
Baclofen medtronic brand
Baclofen novartis brand
Baclofen nu-pharm brand
Baclofen pharmascience brand
Baclofene
Baclofène
Baclofène irex
Baclofène-irex
BaclofèneIrex
Baclofeno
Baclofenum
Baclon®|Kemstro®|Lioresal®
Baclophen
Baclospas
BACLOSPAS-10
beta-(4-Chlorophenyl)gaba
beta-(Aminomethyl)-4-chlorobenzenepropanoate
beta-(Aminomethyl)-4-chlorobenzenepropanoic acid
beta-(Aminomethyl)-p-chlorohydrocinnamate
beta-(Aminomethyl)-p-chlorohydrocinnamic acid
|
beta-(p-Chlorophenyl)-gamma-aminobutyrate
beta-(p-Chlorophenyl)-gamma-aminobutyric acid
Chlorophenyl gaba
Ciba geigy brand OF baclofen
CIBA34,647ba
CIBA-34,647-ba
Ciba-geigy brand OF baclofen
Clofen
DL-4-Amino-3-p-chlorophenylbutanoate
DL-4-Amino-3-p-chlorophenylbutanoic acid
DL-Baclofen
GABA, chlorophenyl
GABLOFEN
g-Amino-b-(p-chlorophenyl)butyrate
g-Amino-b-(p-chlorophenyl)butyric acid
gamma-Amino-beta-(p-chlorophenyl)butyrate
gamma-Amino-beta-(p-chlorophenyl)butyric acid
Gen baclofen
Gen-baclofen
GenBaclofen
Genpharm
Irex brand OF baclofen
Isis brand OF baclofen
Kemstro
Lebic
Lioresal
LIORESAL INTRATH
LYFLEX
Medtronic brand OF baclofen
Novartis brand OF baclofen
Nu baclo
Nu pharm brand OF baclofen
Nu-baclo
NuBaclo
Nu-pharm brand OF baclofen
PCP-GABA
Pharmascience brand OF baclofen
PMS Baclofen
PMSBaclofen
PMS-Baclofen
Β-(4-chlorophenyl)gaba
Β-(aminomethyl)-4-chlorobenzenepropanoate
Β-(aminomethyl)-4-chlorobenzenepropanoic acid
Β-(aminomethyl)-p-chlorohydrocinnamate
Β-(aminomethyl)-p-chlorohydrocinnamic acid
Β-(p-chlorophenyl)-γ-aminobutyrate
Β-(p-chlorophenyl)-γ-aminobutyric acid
Γ-amino-β-(p-chlorophenyl)butyrate
Γ-amino-β-(p-chlorophenyl)butyric acid
|
|
9 |
|
Phenylephrine |
Approved |
Phase 3 |
|
59-42-7 |
6041 |
Synonyms:
(-)-m-Hydroxy-a-(methylaminomethyl)benzyl alcohol
(-)-m-Hydroxy-alpha-(methylaminomethyl)benzyl alcohol
(−)-m-hydroxy-α-(methylaminomethyl)benzyl alcohol
(-)-m-Hydroxy-α-(methylaminomethyl)benzyl alcohol
(R)-3-[-1-HYDROXY-2-(METHYLAMINO)ETHYL]PHENOL
(R)-3-Hydroxy-alpha-((methylamino)methyl)benzenemethanol
AB-101 (PHENYLEPHRINE)
Adrianol
Ak-dilate
Ak-nefrin
Alcon efrin
Alconefrin nasal drops 12
Alconefrin nasal drops 25
Alconefrin nasal drops 50
Alconefrin nasal spray 25
BENZENEMETHANOL, 3-HYDROXY-.ALPHA.-[(METHYLAMINO)METHYL]-, (R)-
BENZENEMETHANOL, 3-HYDROXY-ALPHA-((METHYLAMINO)METHYL)-, (R)-
BENZYL ALCOHOL, M-HYDROXY-ALPHA-((METHYLAMINO)METHYL)-, (-)-
Biomydrin
CYCLOMYDRIL
Dilatair
Dimetane
Dionephrine
Doktors
DUO-MEDIHALER
Duration
Fenilefrina
Fenilefrina [INN-Spanish]
I-phrine
Isophrim
Isophrin
Isopto frin
J8.601K
L-(3-Hydroxyphenyl)-N-methylethanolamine
L-Phenylephedrine
L-Phenylephrine
Mesaton
Mesatone
Mesatonum
Metaoxedrin
Metaoxedrine
Metaoxedrinum
Metasympatol
Metasynephrine
|
Metsatonum
Mezaton
Minims phenylephrine
m-Methylaminoethanolphenol
m-Oxedrine
m-oxedrine|metasynephrine
m-Sympathol
m-Sympatol
m-Synephrine
Mydfrin
Neo synephrine
Neofrin
Neophryn
Neosynephrine
Neo-synephrine
Neo-synephrine nasal drops
Neo-synephrine nasal jelly
Neo-synephrine nasal spray
Neo-synephrine pediatric nasal drops
Nostril
Nostril spray pump
Nostril spray pump mild
Ocugestrin
Ocu-phrin sterile eye drops
Ocu-phrin sterile ophthalmic solution
PEF100
Phenoptic
PHENYLEPHRINE
Phenylephrine hydrochloride
Phenylephrine minims
Phenylephrine tannate
Phenylephrinum
Phenylephrinum [INN-Latin]
Prefrin
Prefrin liquifilm
Pyracort D
R(-)-Mezaton
R(-)-Phenylephrine
Relief eye drops for red eyes
Rhinall
Spersaphrine
Tannate, phenylephrine
Vicks sinex
Visadron
|
|
10 |
|
Oxymetazoline |
Approved, Investigational |
Phase 3 |
|
1491-59-4 |
4636 |
Synonyms:
2-(4-Tert-butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazoline
3-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethylphenol
6-t-Butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol
6-Tert-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol
Afrin
Afrin®|oxymethazoline|SCH-9384|Upneeq® (opthalmic solution)|Vicks Sinex®
Hydrochloride, oxymetazoline
OCUCLEAR
Operil
Oximetazolinum
|
Oxymetazolina
OXYMETAZOLINE
Oxymétazoline
Oxymetazoline hydrochloride
Oxymetazoline hydrochloride crystalline
Oxymetazolinum
Oxymethazoline
Oxymetozoline
SCH-9384
VICKS SINEX
|
|
11 |
|
Valproic acid |
Approved, Investigational |
Phase 3 |
|
99-66-1 |
3121 |
Synonyms:
(N-C3H7)2chcooh
(S)-2-Propyl-4-pentanoate
(S)-2-Propyl-4-pentanoic acid
2 Propylpentanoic acid
2-N-PROPYL-4-PENTENOIC ACID
2-N-Propyl-N-valerate
2-N-Propyl-N-valeric acid
2-Propylpentanoate
2-PROPYL-pentanoate
2-Propylpentanoic acid
2-PROPYL-pentanoIC ACID
2-Propylvalerate
2-Propylvaleric acid
44089
4-Heptanecarboxylate
4-Heptanecarboxylic acid
A-44090
A-44090|Depakote®|Epilim®|valproate sodium
Acetate, dipropyl
Acid, propylisopropylacetic
Acid, valproic
Acide valproique
acide valproïque
Acido valproico
ácido valproico
Acidum valproicum
Alti-valproic
Apo-divalproex
Apo-valproic
Apo-valproic syrup
Avugane
Baceca
Calcium valproate
Calcium, valproate
Convulex
Convulsofin
Delepsine
Depacon
Depakene
Depakin
Depakin chrono
Depakine
Depakine chrono
Depakote
Deproic
Di-N-propylacetate
Di-N-propylacetic acid
Di-N-propylessigsaeure
Di-N-propylessigsaure
Di-n-propylessigsäure
Dipropyl acetate
Dipropylacetate
Dipropylacetic acid
Divalproex
Divalproex sodium
DOM-divalproex
Dom-valproate
DOM-valproic
Dom-valproic acid
DOM-valproic acid e.c.
Dom-valproic acid syrup
DPA
Epiject i.v.
Epilex
Epilim
|
Epival
Epival er
Ergenyl
Gen-divalproex
Kyselina 2-propylvalerova
LEP321
Magnesium valproate
Med valproic
Mylproin
Myproate
Myproic acid
N-Dipropylacetic acid
N-DPA
Novo-divalproex
Novo-valproic
Novo-valproic - ecc
Novo-valproic soft gel cap
NSC-93819
Nu-valproic
PEAC
Penta-valproic
PHL-Valproate
PHL-Valproic acid
PHL-Valproic acid e.c.
PMS-Divalproex
PMS-Valproate
PMS-Valproic acid
PMS-Valproic acid e.c.
Propylisopropylacetic acid
Propylvaleric acid
Ratio-valproic - ecc
S(-)-4-En-valproate
S(-)-4-En-valproic acid
S-2-N-Propyl-4-pentenoate
S-2-N-Propyl-4-pentenoic acid
Sandoz valproic
Savicol
Semisodium valproate
Sodium hydrogen divalproate
Sodium valproate
Sodium, divalproex
Sodium, valproate
Sprinkle
STAVZOR
Valcote
Valparin
Valproate
Valproate calcium
Valproate semisodique [French]
Valproate semisodium
Valproate sodium
Valproate, calcium
Valproate, magnesium
Valproate, semisodium
Valproate, sodium
Valproato semisodico [Spanish]
Valproatum seminatricum [Latin]
VALPROIC ACID
Valproic acid usp
Valproic acid USP24
Valproic acid, sodium salt (2:1)
Valproinsaeure
Valproinsäure
VPA
Vupral
|
|
12 |
|
Pentoxifylline |
Approved, Investigational |
Phase 3 |
|
6493-05-6 |
4740 |
Synonyms:
Agapurin
BL-191
BL-191|Trental®
C04AD03
EHT0201
NEOTREN MR
NSC-637086
Oxpentifylline
Pentoxifilina
|
Pentoxifyllin
Pentoxifylline
Pentoxifyllinum
Pentoxil
Torental
Trental
TRENTAL 100
TRENTAL 400
|
|
13 |
|
Ethanol |
Approved |
Phase 3 |
|
64-17-5 |
702 |
Synonyms:
[CH2Me(OH)]
[OEtH]
1-Hydroxyethane
ABLYSINOL
Absolute alcohol
Absolute ethanol
Absolute ethyl alcohol
Aethanol
Aethylalkohol
Alcare hand degermer
Alcohol
Alcohol (ethyl)
Alcohol anhydrous
Alcohol denatured
ALCOHOL DETERMINATION--ALCOHOL
Alcohol etilico
Alcohol etílico
Alcohol, absolute
Alcohol, Dehydrated
Alcohol, denatured
ALCOHOL, DILUTED
Alcohol, ethyl
Alcohol, grain
ALCOHOL, RUBBING
Alcohols
Alcool ethylique
Alcool éthylique
Alcool etilico
Algrain
Alkohol
Alkoholu etylowego
Aminoethanol
Anhydrol
Anhydrous alcohol
Anhydrous ethanol
Äthanol
Äthylalkohol
B3324
Beta-Aminoethanol
Beta-Aminoethyl Alcohol
Beta-Ethanolamine
Beta-Hydroxyethylamine
C2H5OH
Caswell No. 426
Colamine
Cologne spirit
Cologne spirits
Dehydrated alcohol
Dehydrated ethanol
Denatured alcohol
Denatured Alcohol Cd-10
Denatured Alcohol Cd-5
Denatured Alcohol Cd-5a
Denatured Alcohol Sd-1
Denatured Alcohol Sd-13a
Denatured Alcohol Sd-17
Denatured Alcohol Sd-23a
Denatured Alcohol Sd-28
Denatured Alcohol Sd-30
Denatured Alcohol Sd-39b
Denatured Alcohol Sd-39c
Denatured Alcohol Sd-3a
Denatured Alcohol Sd-40m
Denatured ethanol
Desinfektol el
Diluted alcohol
Distilled spirits
DRINKING ALCOHOL
E1510
Envision Conditioner Pdd 9020
ETA
Etanol
|
Etanolo
ETHANOL
éthanol
Ethanol 200 proof
Ethanol Absolute
Ethanol Absolute Bp
Ethanol Anhydrous
Ethanol Extra Pure
Ethanol solution
Ethanol, Silent Spirit
Ethicap
Ethyl alc
Ethyl alcohol
Ethyl Alcohol & Water, 10%
Ethyl Alcohol & Water, 20%
Ethyl Alcohol & Water, 30%
Ethyl Alcohol & Water, 40%
Ethyl Alcohol & Water, 5%
Ethyl Alcohol & Water, 50%
Ethyl Alcohol & Water, 60%
Ethyl Alcohol & Water, 70%
Ethyl Alcohol & Water, 80%
Ethyl Alcohol & Water, 95%
Ethyl Alcohol & Water, 96%
Ethyl alcohol anhydrous
Ethyl alcohol in alcoholic beverages
Ethyl alcohol usp
Ethyl Alcohol, Anhydrous
Ethyl Alcohol, Denatured
Ethyl hydrate
Ethyl hydroxide
Ethylol
Ethylolamine
EtOH
FEMA NO. 2419
Fermentation alcohol
Glycinol
Grain alcohol
Hinetoless
HSDB 531
Hydroxyethane
Infinity pure
Jaysol
Jaysol S
Lux
METHYLATED MINERAL
Methylated Spirit Mineralised
Methylcarbinol
Molasses alcohol
NCI-C03134
NSC-85228
PM-6193-200
Potato alcohol
Punctilious ethyl alcohol
Pyro
Reagent Alcohol
Silent spirit
SPIRIGEL
Spirit
Spirits OF wine
Spiritus vini
Spirt
SURG
Synasol
Tecsol
Tecsol C
Thanol
Thiofaco M-50
Undenatured ethanol
USAF EK-1597
VODKA
|
|
14 |
|
Peppermint oil |
Approved, Investigational |
Phase 3 |
|
8006-90-4 |
|
Synonyms:
English black mint oil
Mentha crispa oil
Mentha dumetorum oil
Mentha piperita (peppermint) leaf water
Mentha piperita (peppermint) oil
Mentha piperita flowering top oil
Mentha piperita oil
Mentha X piperita oil
Menthae piperitae aetheroleum
Oil of peppermint
|
Pepermint oil
Peppermint american far west bulked
Peppermint american willamette natural
Peppermint flowering top oil
Peppermint indian rectified
Peppermint oil america
Peppermint oil mongolia
Peppermint oil yakima
Peppermint volatile oil
|
|
15 |
|
Peppermint |
Approved |
Phase 3 |
|
|
|
Synonyms:
|
16 |
|
Cannabidiol |
Approved, Investigational |
Phase 3 |
|
13956-29-1 |
521372 644019 |
Synonyms:
(−)-trans-2-p-mentha-1,8-dien-3-yl-5-pentylresorcinol
(−)-trans-cannabidiol
(1'R,2'R)-5'-methyl-4-pentyl-2'-(prop-1-en-2-yl)-1',2',3',4'-tetrahydrobiphenyl-2,6-diol
BTX-1503
CANNABIDIOL
CBD
CBD|Epidiolex®|GWP42003-P|nabiximols (CBD + THC, fixed-dose oral spray)|Sativex® (CBD + THC, fixed-dose oral spray)
|
EPIDIOLEX
GWP42003
GWP-42003
GWP42003-P
GWP-42003-P
Δ1(2)-trans-cannabidiol
|
|
17 |
|
Dronabinol |
Approved, Illicit |
Phase 3 |
|
1972-08-3 |
16078 |
Synonyms:
&Delta
Δ<sup>9</sup>-THC|Abbott 40566|delta9-THC|Marinol®|tetrahydrocannabinol|THC
(-)- delta 9-Tetrahydrocannabinol
(-)-3,4-trans-delta1-Tetrahydrocannabinol
(-)-3,4-trans-Δ1-Tetrahydrocannabinol
(-)-delta 1-Tetrahydrocannabinol
(-)-delta 9-THC
(-)-delta 9-trans-Tetrahydrocannabinol
(-)-delta1-Tetrahydrocannabinol
(-)-delta9-Tetrahydrocannabinol
(-)-delta9-THC
(-)-delta9-trans-Tetrahydrocannabinol
(-)-trans-delta 1-Tetrahydrocannabinol
(-)-trans-delta 9-Tetrahydrocannabinol
(-)-trans-delta 9-THC
(-)-trans-delta1-Tetrahydrocannabinol
(-)-trans-delta9-Tetrahydrocannabinol
(-)-trans-delta9-THC
(-)-trans-Δ1-Tetrahydrocannabinol
(-)-trans-Δ9-Tetrahydrocannabinol
(-)-trans-Δ9-THC
(-)-Δ1-Tetrahydrocannabinol
(-)-Δ9-Tetrahydrocannabinol
(-)-Δ9-THC
(-)-Δ9-trans-tetrahydrocannabinol
(L)-delta 1-Tetrahydrocannabinol
(l)-delta1-Tetrahydrocannabinol
(l)-Δ1-Tetrahydrocannabinol
14C-delta 1-Tetrahydrocannabinol
1-trans-delta 9-Tetrahydrocannabinol
1-trans-delta-9-Tetrahydrocannabinol
1-trans-Δ-9-tetrahydrocannabinol
3-Pentyl-6,6,9-trimethyl-6a,7,8,10a-tetrahydro-6H-dibenzo(b,D)pyran-1-ol
6,6,9-Trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol
6H-DIBENZO(B,D)PYRAN-1-OL, 6A,7,8,10A-TETRAHYDRO-6,6,9-TRIMETHYL-3-PENTYL-, (6AR,10AR)-
9 Ene tetrahydrocannabinol
9-Ene-tetrahydrocannabinol
9-tetrahydrocannabinol
9-THC
ABBOTT 40566
ABBOTT-40566
Dea No. 7369
Dea No. 7370
delta 1-Tetrahydrocannabinol
delta 1-THC
delta 9-Tetrahydrocannabinol
delta 9-THC
delta 9-trans-Tetrahydrocannabinol
Delta(1)-Tetrahydrocannabinol
delta(1)-THC
delta(9)-Tetrahydrocannabinol
Delta(9)-THC
delta1-Tetrahydrocannabinol
|
delta1-THC
delta9-Tetrahydrocannabinol
DELTA-9-TETRAHYDROCANNABINOL
delta9-THC
DELTA-9-THC
delta9-trans-Tetrahydrocannabinol
Deltanyne
Dronabinol
Dronabinol [Usan:Inn]
DRONABINOLEN
Dronabinolum
Dronabinolum [Latin]
Exocyclic delta (9)(11)-tetrahydrocannabiol
J882F
L-delta 1-trans-Tetrahydrocannabinol
l-delta1-trans-Tetrahydrocannabinol
L-trans-delta 9-Tetrahydrocannabinol
l-trans-delta9-Tetrahydrocannabinol
l-trans-Δ9-Tetrahydrocannabinol
l-Δ1-trans-Tetrahydrocannabinol
Marinol
NSC-134454
Primolut
QCD 84924
QCD-84924
Solvay brand OF tetrahydrocannabinol
SP 104
SP-104
Syndros
Tetrahydrocannabinol
Tetrahydrocannabinol, (6ar-cis)-isomer
Tetrahydrocannabinol, (6as-cis)-isomer
Tetrahydrocannabinol, (6a-trans)-isomer
Tetrahydrocannabinol, trans isomer
Tetrahydrocannabinol, trans-(+-)-isomer
Tetrahydrocannabinol, trans-isomer
THC
trans-(-)-delta9-Tetrahydrocannabinol
trans-(-)-Δ9-Tetrahydrocannabinol
trans-delta (-)-9-Tetrahydrocannabinol
trans-delta 9-Tetrahydrocannabinol
trans-delta9-Tetrahydrocannabinol
trans-Δ9-Tetrahydrocannabinol
Δ(1)-tetrahydrocannabinol
Δ(9)-THC
Δ1-Tetrahydrocannabinol
Δ1-THC
Δ9-tetrahydrocannabinol
Δ-9-tetrahydrocannabinol
Δ9-THC
Δ-9-THC
Δ9-trans-Tetrahydrocannabinol
|
|
18 |
|
Arbaclofen Placarbil |
Investigational |
Phase 3 |
|
847353-30-4 |
|
Synonyms:
ARBACLOFEN PLACARBIL
XP19986
|
|
|
19 |
|
Trichostatin A |
Experimental |
Phase 3 |
|
58880-19-6 |
5562 444732 |
Synonyms:
A-300-I
ANTIBIOTIC A-300
GNF-PF-1011
N-Hydroxy7-[4-(dimethylamino)phenyl]-4,6-dimethyl-7-oxohepta-2,4-dienimidate
|
TRICHOSTATIN
TRICHOSTATIN(S)
TSA
|
|
20 |
|
Nabiximols |
Investigational |
Phase 3 |
|
56575-23-6 |
|
Synonyms:
CANNABINOIDS
GW 1000
GW 1000-02
GW-1000
|
Nabiximols
SAB 378
SAB-378
SATIVEX
|
|
21 |
|
Neem |
|
Phase 2, Phase 3 |
|
|
|
22 |
|
Anticonvulsants |
|
Phase 3 |
|
|
|
23 |
|
Potassium Channel Blockers |
|
Phase 3 |
|
|
|
24 |
|
Psychotropic Drugs |
|
Phase 3 |
|
|
|
25 |
|
Protective Agents |
|
Phase 3 |
|
|
|
26 |
|
Platelet Aggregation Inhibitors |
|
Phase 3 |
|
|
|
27 |
|
Antioxidants |
|
Phase 3 |
|
|
|
28 |
|
Radiation-Protective Agents |
|
Phase 3 |
|
|
|
29 |
|
Phosphodiesterase Inhibitors |
|
Phase 3 |
|
|
|
30 |
|
Vasodilator Agents |
|
Phase 3 |
|
|
|
31 |
|
rimabotulinumtoxinB |
|
Phase 2, Phase 3 |
|
|
|
32 |
|
Analgesics |
|
Phase 3 |
|
|
|
33 |
|
Phytosterol |
|
Phase 3 |
|
|
|
34 |
|
Riluzole |
Approved, Investigational |
Phase 2 |
|
1744-22-5 |
5070 |
Synonyms:
2 Amino 6 trifluoromethoxybenzothiazole
2-Amino-6-trifluoromethoxybenzothiazole
Aventis behring brand OF riluzole
Aventis brand OF riluzole
BHV-0223
Impax brand OF riluzole
Rhone poulenc rorer brand OF riluzole
Rhone-poulenc rorer brand OF riluzole
Rilutek
|
Rilutek®|RP-54274|Tiglutik® (thickened oral suspension)
RILUZOL
RILUZOLE
Riluzole aventis brand
Riluzole impax brand
RILUZOLUM
RP-54274
TEGLUTIK
TIGLUTIK KIT
|
|
35 |
|
Metformin |
Approved |
Phase 2 |
|
1115-70-4, 657-24-9 |
4091 |
Synonyms:
[<sup>14</sup>C]-metformin
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
1-CARBAMIMIDAMIDO-N,N-DIMETHYLMETHANIMIDAMIDE
Apo-Metformin
BOLAMYN SR
Diabefagos
Diabex
Diaformin
DIAGEMET XL
Dianben
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
DMBG
Fortamet
Gen-Metformin
GLUCAMET 500
GLUCAMET 850
GLUCIENT SR
Glucophage
GLUCOPHAGE SR
GLUCOPHAGE XR
Glumetza
Glycon
GLYFORMIN
HCL, Metformin
Hydrochloride, metformin
JANUMET
LA 6023
LA-6023
|
LEDERMETIN
Meguan
METABET SR
Metformin
Metformin HCL
Metformin hydrochloride
Metformina
Metformine
Metforminum
Metiguanide
METSOL
MILFORM
Mylan-Metformin
N(1),N(1)-Dimethylbiguanide
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylguanylguanidine
N,N-Dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
Novo-Metformin
NSC-91485
Nu-Metformin
Obimet
ORABET
PMS-Metformin
Ran-Metformin
Ratio-Metformin
Riomet
Sandoz Metformin
SUKKARTO SR
Teva-Metformin
XLA399
|
|
36 |
|
Acetylcholine |
Approved, Investigational |
Phase 2 |
|
51-84-3 |
187 |
Synonyms:
[2-(ACETYLOXY)ETHYL]TRIMETHYLAZANIUM
2-(Acetyloxy)-N,N,N-trimethylethanaminium
2-ACETOXYETHYL(TRIMETHYL)AMMONIUM
2-ACETYLOXYETHYL(TRIMETHYL)AMMONIUM
2-ACETYLOXYETHYL(TRIMETHYL)AZANIUM
Acetilcolina cusi
Acetyl choline ion
Acetylcholine
Acetylcholine bromide
Acetylcholine cation
Acetylcholine chloride
Acetylcholine fluoride
Acetylcholine hydroxide
Acetylcholine iodide
Acetylcholine L tartrate
Acetylcholine L-tartrate
Acetylcholine perchlorate
Acetylcholine picrate
Acetylcholine picrate (1:1)
Acetylcholine sulfate (1:1)
ACETYLCHOLINE, ACH
Acetylcholinium: acetyl-choline
|
ACh
ACh|E1001|O-acetylcholine
Alcon brand OF acetylcholine chloride
Azetylcholin
Bournonville brand OF acetylcholine chloride
Bromide, acetylcholine
Bromoacetylcholine
Chloroacetylcholine
Choline acetate
Choline acetate (ester)
Choline acetic acid
Ciba vision brand OF acetylcholine chloride
Cusi, acetilcolina
E1001
Fluoride, acetylcholine
Hydroxide, acetylcholine
Iodide, acetylcholine
Iolab brand OF acetylcholine chloride
L-Tartrate, acetylcholine
Miochol
O-Acetylcholine
Perchlorate, acetylcholine
|
|
37 |
|
Moxifloxacin |
Approved, Investigational |
Phase 2 |
|
186826-86-8, 354812-41-2, 151096-09-2 |
152946 |
Synonyms:
1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4as,7as)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylate
1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4as,7as)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid
1-Cyclopropyl--7-(2,8-diazabicyclo(4.3.0)non-8-yl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
Actira
Avalox
Avelox
AVELOX I.V.
BAY 12-8039
|
Izilox
MOXIFLOXACIN
Moxifloxacin HCl
Moxifloxacin hydrochloride
Moxifloxacino
Octegra
Proflox
VIGAMOX
|
|
38 |
|
Nabilone |
Approved, Investigational |
Phase 2 |
|
51022-71-0 |
39860 5284592 |
Synonyms:
Cesamet
Cesamet®|LY 109514|LY-109514
CPD 109514
CPD-109514
Lilly brand OF nabilone
Nabilon
Nabilona
|
Nabilone
Nabilone, (6ar-trans)-isomer
Nabilone, (6as-trans)-isomer
Nabilone, (cis-(+-))-isomer
Nabilone, (trans-(+-))-isomer
Nabilonum
|
|
39 |
|
Levetiracetam |
Approved |
Phase 2 |
|
102767-28-2 |
441341 5284583 |
Synonyms:
AGB-101
alpha Ethyl 2 oxo 1 pyrrolidineacetamide
alpha-Ethyl-2-oxo-1-pyrrolidineacetamide
DESITREND
e Keppra
ELEPSIA XR
Etiracetam
Etiracetam, R isomer
Etiracetam, R-isomer
Etiracetam, S isomer
Etiracetam, S-isomer
Keppra
KEPPRA XR
Keppra®|Spritam®|UCB L059|UCB-L 059
LEVETIRACETAM
Levetiracetam [INN]
LEVETIRACETAM IN SODIUM CHLORIDE
|
Levetiracetame
Levetiracetamum
Levetiracetamum [INN-Latin]
Levitiracetam
MATEVER
N03AX14
R-Isomer etiracetam
S-Isomer etiracetam
SPRITAM
UCB brand OF levetiracetam
Ucb L059
Ucb L060
UCB-22059
Ucb-L059
UcbL060
Ucb-L060
|
|
40 |
|
Miglustat |
Approved |
Phase 2 |
|
72599-27-0 |
51634 |
Synonyms:
Brazaves
BuDNJ
Butyldeoxynojirimycin
MIGLUSTAT
Miglustatum
N-(N-Butyl)deoxynojirimycin
N-(N-Butyl)deoxy-nojirimycin
NB-DNJ
N-Butyl deoxynojirimycin
|
N-Butyl-1-deoxynojirimycin
N-butyl-1-deoxynojirimycin|NB-DNJ|Zavesca®
N-Butyldeoxynojirimycin
N-Butylmoranoline
OGT 918
OGT-918
SC-48334
Zavesca
|
|
41 |
|
Atorvastatin |
Approved |
Phase 2 |
|
134523-00-5 |
60823 |
Synonyms:
(3R,5R)-7-(2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoic acid
(3R,5R)-7-[2-(4-FLUOROPHENYL)-3-PHENYL-4-(PHENYLCARBAMOYL)-5-(PROPAN-2-YL)-1H-PYRROL-1-YL]-3,5-DIHYDROXYHEPTANOIC ACID
(R-(R*,r*))-2-(4-fluorophenyl)-b,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-b,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
(R-(R*,r*))-2-(4-fluorophenyl)-b,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-b,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
(R-(R*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
(R-(R*,r*))-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
7-[2-(4-FLUORO-phenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-3,5-dihydroxy-heptanoate
7-[2-(4-FLUORO-phenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-3,5-dihydroxy-heptanoIC ACID
Anhydrous, atorvastatin calcium
Atogal
Atorlip
Atorpic
ATORVASTATIN
Atorvastatin acid
Atorvastatin calcium
Atorvastatin calcium anhydrous
Atorvastatin calcium hydrate
Atorvastatin calcium trihydrate
Atorvastatin, calcium salt
Atorvastatina
Atorvastatine
Atorvastatinum
Calcium anhydrous, atorvastatin
Calcium hydrate, atorvastatin
Calcium salt atorvastatin
Calcium trihydrate, atorvastatin
Calcium, atorvastatin
|
Cardyl
Faboxim
Hipolixan
Hydrate, atorvastatin calcium
LCF872
Lipitor
Lipitor®
Lipotropic
Lipovastatinklonal
Liprimar
Liptonorm
Lowden
Normalip
PREVENCOR
Sincol
Sortis
Sotis
TAHOR
Torvacard
Torvast
Totalip
Tozalip
Trihydrate, atorvastatin calcium
Tulip
Vastina
Xanator
Xarator
Xavator
ZARATOR
Zurinel
|
|
42 |
|
Chenodeoxycholic acid |
Approved |
Phase 2 |
|
474-25-9 |
10133 |
Synonyms:
(+)-CHENODEOXYCHOLATE
(+)-CHENODEOXYCHOLIC ACID
(3A,5B,7A)-3,7-DIHYDROXY-CHOLAN-24-OATE
(3A,5B,7A)-3,7-DIHYDROXY-CHOLAN-24-OIC ACID
(4R)-4-[(1S,2S,5R,7S,9R,10R,11S,14R,15R)-5,9-DIHYDROXY-2,15-DIMETHYLTETRACYCLO[8.7.0.0^{2,7}.0^{11,15}]HEPTADECAN-14-YL]PENTANOIC ACID
(4R)-4-[(3R,5S,7R,8R,9S,10S,13R,14S,17R)-10,13-DIMETHYL-3,7-BIS(OXIDANYL)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-TETRADECAHYDRO-1H-CYCLOPENTA[A]PHENANTHREN-17-YL]PENTANOIC ACID
(4R)-4-[(3R,5S,7R,8R,9S,10S,13R,14S,17R)-3,7-DIHYDROXY-10,13-DIMETHYL-2,3,4,5,6,7,8,9,11,12,14,15,16,17-TETRADECAHYDRO-1H-CYCLOPENTA[A]PHENANTHREN-17-YL]PENTANOIC ACID
(4R)-4-[(3R,5S,7R,8R,9S,10S,13R,14S,17R)-3,7-DIHYDROXY-10,13-DIMETHYL-2,3,4,5,6,7,8,9,11,12,14,15,16,17-TETRADECAHYDRO-1H-CYCLOPENTA[A]PHENANTHREN-17-YL]VALERIC ACID
3A,7A-DIHYDROXY-5B,14A,17B-CHOLANATE
3A,7A-DIHYDROXY-5B,14A,17B-CHOLANIC ACID
3A,7A-DIHYDROXY-5B-CHOLAN-24-OATE
3A,7A-DIHYDROXY-5B-CHOLAN-24-OIC ACID
3A,7A-DIHYDROXY-5B-CHOLANATE
3A,7A-DIHYDROXY-5B-CHOLANIC ACID
3alpha,7alpha-Dihydroxy-5beta-cholanate
3ALPHA,7ALPHA-DIHYDROXY-5BETA-CHOLANIC ACID
3Α,7α-dihydroxy-5β-cholanate
3Α,7α-dihydroxy-5β-cholanic acid
7A-HYDROXY-DESOXYCHOLSAEURE
7a-Hydroxylithocholate
7a-Hydroxylithocholic acid
7alpha-Hydroxylithocholate
7ALPHA-HYDROXYLITHOCHOLIC ACID
7Α-hydroxylithocholate
7Α-hydroxylithocholic acid
Acid, chenic
Acid, chenique
Acid, chenodeoxycholic
Acid, gallodesoxycholic
Acide chenodeoxycholique
Acido chenodeoxicholico
Acidum chenodeoxycholicum
Anthropodeoxycholate
ANTHROPODEOXYCHOLIC ACID
Anthropodesoxycholate
|
ANTHROPODESOXYCHOLIC ACID
Antigen brand OF chenodeoxycholic acid
CDCA
CDCA|Chenix®|chenodeoxycholate|Chenodiol®|Leadiant® (formerly Chenodeoxycholic acid sigma-tau)
Chenate
CHENDOL 125
CHENDOL 250
CHENIC ACID
Chenique acid
CHENIX
CHENOCEDON
CHENOCHOLIC ACID
CHENODEOXYCHOLATE
Chenodeoxycholate, sodium
CHENODEOXYCHOLIC ACID
CHENODESOXYCHOLIC ACID
CHENODESOXYCHOLSAEURE
CHENODIOL
CHENOFALK
Chenophalk
COMBIDOL
Estedi brand OF chenodeoxycholic acid
Falk brand OF chenodeoxycholic acid
Gallodesoxycholate
GALLODESOXYCHOLIC ACID
Henohol
LITHOFALK
NSC-657949
Quenobilan
Quenocol
Sodium chenodeoxycholate
Solvay brand OF chenodeoxycholic acid
Tramedico brand OF chenodeoxycholic acid
XENBILOX
Zambon brand OF chenodeoxycholic acid
|
|
43 |
|
Evolocumab |
Approved |
Phase 1, Phase 2 |
|
1256937-27-5 |
|
Synonyms:
AMG-145
AMG-145|AMG145|Repatha®
EVOLOCUMAB
|
REPATHA
REPATHA SURECLICK
|
|
44 |
|
Resveratrol |
Investigational |
Phase 2 |
|
501-36-0 |
445154 |
Synonyms:
(E)-2-(3,5-Dihydroxyphenyl)-1-(4-hydroxyphenyl)ethene
(E)-3,4',5-Trihydroxystilbene
(E)-3,4’,5-Trihydroxystilbene
(e)-5-(2-(4-Hydroxyphenyl)ethenyl)-1,3-benzenediol
(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol
(E)-5-(p-Hydroxystyryl)resorcinol
(E)-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol
(e)-Resveratrol
3,4',5-Stilbenetriol
3,4',5-stilbenetriol|3,5,4'-trihydroxystilbene|trans-resveratrol
3,4',5-Trihydroxystilbene
3,4',5-Trihydroxy-trans-stilbene
3,4’,5-Stilbenetriol
3,4’,5-Trihydroxystilbene
3,4’,5-Trihydroxy-trans-stilbene
|
3,5,4'-Trihydroxystilbene
3,5,4'-TRIHYDROXY-TRANS-STILBENE
5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol
5-[(e)-2-(4-Hydroxyphenyl)vinyl]benzene-1,3-diol
BIA 6-512
BIA-6-512
NSC-327430
Resveratrol
SRT 501
SRT-501
trans Resveratrol
trans-3,4',5 - Trihydroxystilbene
trans-3,5,4’-Trihydroxystilbene
trans-3,5,4'-Trihydroxystilbene
trans-Resveratrol
|
|
45 |
|
Tolperisone |
Investigational |
Phase 2 |
|
728-88-1 |
|
Synonyms:
MYDETON
N-553 [AS HYDROCHLORIDE]
N-553 FREE BASE
|
NSC-107321
TOLPERISONE
TOLPERISONE HCL
|
|
46 |
|
Neuroprotective Agents |
|
Phase 2 |
|
|
|
47 |
|
Neurotransmitter Agents |
|
Phase 2 |
|
|
|
48 |
|
abobotulinumtoxinA |
|
Phase 2 |
|
|
|
Synonyms:
ABOBOTULINUMTOXINA
BONT/A
BONTOXILYSIN A
BOTOX
BOTULINUM TOXIN TYPE A
|
BOTULINUM TOXINS, TYPE A
BOTULOTOXIN A
BTX-A
ONABOTULINUMTOXINA
|
|
49 |
|
Botulinum Toxins, Type A |
|
Phase 2 |
|
|
|
50 |
|
Botulinum Toxins |
|
Phase 2 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 596)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A Randomized Controlled Trial of Rectus Femoris Tenotomy Versus Botulinum Toxin A for Stiff Knee Gait After Stroke |
Unknown status |
NCT02114736 |
Phase 4 |
Botulinum Toxin injection in the rectus femoris muscle |
2 |
Dose-response Relationship of Botullinum Toxin (DWP 450) for Finger Flexor Spasticity |
Unknown status |
NCT03517319 |
Phase 4 |
Normal Saline 0.9% 1.2 ml;Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 15 U;Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 30 U;Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 50 U;Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 70 U |
3 |
Phase III Study of Botulinum Toxin A Injection for Lower Limbs Spasticity in Subacute Stroke Adults |
Unknown status |
NCT02505802 |
Phase 4 |
BoNT-A injection |
4 |
Optimal Dose of Extracorporeal Shock Wave Therapy After Botulinum Toxin Type A Injection for Post-stroke Spasticity |
Unknown status |
NCT02358005 |
Phase 4 |
|
5 |
Effects of Functional Electrical Stimulation on Gait in Children With Hemiplegic and Diplegic Cerebral Palsy |
Unknown status |
NCT02462018 |
Phase 4 |
|
6 |
Upper Extremity Rehabilitation Using Robot and Botulinum Toxin |
Unknown status |
NCT02228863 |
Phase 4 |
|
7 |
Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity |
Unknown status |
NCT01786005 |
Phase 4 |
|
8 |
Asian Multicentre, Double Blind, Randomised, Placebo Controlled Pilot Study, to Assess the Impact of Dysport® Intramuscular Injections When Administered Within the First 12 Weeks After Stroke on the Time to Spasticity Progression in Adult Subjects With Upper Limb (UL) Spasticity. |
Completed |
NCT02321436 |
Phase 4 |
Placebo |
9 |
Impact of Injection Techniques on the Effectiveness of Botulinum Toxin for the Treatment of Post Stroke Upper Limb Spasticity |
Completed |
NCT02757404 |
Phase 4 |
Ultrasonography guidance injection of Meditoxin®.;Electrical stimulation guidance injection of Meditoxin®.;Manual needle placement injection of Meditoxin®. |
10 |
Myobloc Atrophy Study |
Completed |
NCT02052024 |
Phase 4 |
Botox;MYOBLOC |
11 |
Effects of Repeated Use of Botulinum Neurotoxin Type A (BoNT/A) Free of Complexing Proteins in the Spastic Equinovarus Foot in Stroke Patients: A Randomized Clinical Trial |
Completed |
NCT03044080 |
Phase 4 |
IncobotulinumtoxinA;OnabotulinumtoxinA |
12 |
A Prospective, Multi-center, Single Arm, Open-label, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of MEDITOXIN® in Treatment of Post Stroke Upper Limb Spasticity |
Completed |
NCT03908580 |
Phase 4 |
Meditoxin |
13 |
Placebo-Controlled Trial of BOTOX® Versus Zanaflex® for the Treatment of Subjects With Post Stroke Upper Limb Spasticity |
Completed |
NCT00430196 |
Phase 4 |
BOTOX®;Zanaflex® |
14 |
Imaging of 3D Innervation Zone Distribution in Spastic Muscles From High-density Surface |
Completed |
NCT03302741 |
Phase 4 |
Botulinum neurotoxin (BTX) |
15 |
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Incobotulinumtoxin Type A for the Functional Improvement of Lower Extremity Spasticity in Patients With Multiple Sclerosis |
Completed |
NCT01968902 |
Phase 4 |
|
16 |
A Multicentre, Double-blind, Randomised, Parallel Group, Placebo-controlled Study of the Effect of Long-term Treatment With Sativex on Cognitive Function and Mood of Patients With Spasticity Due to Multiple Sclerosis |
Completed |
NCT01964547 |
Phase 4 |
Sativex;Placebo |
17 |
BOTOX® Economic Spasticity Trial (BEST) |
Completed |
NCT00549783 |
Phase 4 |
|
18 |
Does Botulinum Toxin A Make Walking Easier in Children With Cerebral Palsy? |
Completed |
NCT02546999 |
Phase 4 |
botox;placebo |
19 |
A Randomized, Controlled, Open-label, Parallel-group, Multi-center Study to Compare the Effect of Intrathecal Baclofen Therapy Versus Best Medical Treatment on Severe Spasticity in Post-stroke Patients After 6 Months Active Treatment |
Completed |
NCT01032239 |
Phase 4 |
intrathecal baclofen |
20 |
Vanderbilt University Spasticity Management Program Evaluation Plan |
Completed |
NCT00179114 |
Phase 4 |
Botulinum Toxin Type A;Intrathecal baclofen administered by the Medtronic SyncroMed(TM) pump (ITB) |
21 |
Comparative Efficacy of Three Preparations of Botox-A in Treating Spasticity |
Completed |
NCT00178646 |
Phase 4 |
Botox |
22 |
Hand Rehabilitation Using Botulinum Toxin and Functional Electrical Stimulation Among Stroke Patients With Limitation of Finger Extension Due to Spasticity- Pilot Study |
Completed |
NCT03549975 |
Phase 4 |
Botulinum Toxin Type A 100 unit/Vial (Product) |
23 |
A Prospective Phase IV, Multicentre, Placebo-controlled Study to Demonstrate Changes in the Quality of Life Following DYSPORT Intramuscular Injection in the Treatment of Upper Limb Spasticity in Adult Post-Stroke Patients |
Completed |
NCT00216411 |
Phase 4 |
Placebo |
24 |
A 24-week Prospective, Multicentre, Randomised, Double-blind, Placebo Controlled Study of Dysport® Injection for the Treatment of Upper Limb Spasticity in Early Stroke. |
Completed |
NCT00234546 |
Phase 4 |
Placebo |
25 |
Study of the Effects on Motor Recovery of Early Post-stroke Spasticity Treatment: Double Blinded Comparison Between Botulinum Toxin and Baclofen. |
Completed |
NCT02462317 |
Phase 4 |
botulinum A toxin;Baclofen;Placebo toxin;placebo baclofen |
26 |
Multi-center, Single Arm, Open-label, Phase IV Clinical Trial to Evaluate the Safety and Efficacy of MEDITOXIN® in Children With Cerebral Palsy |
Completed |
NCT01256021 |
Phase 4 |
Botulinum Toxin Type A |
27 |
An Efficacy Comparison of Botulinum Toxin A Injection Into Two Different Sites in Gastrocnemius Muscle for the Treatment of Spastic Patients, Randomized Controlled Trial |
Completed |
NCT01278576 |
Phase 4 |
BOTOX-A® |
28 |
Intrathecal (IT) Baclofen Drug Distribution Pilot Study |
Completed |
NCT02903823 |
Phase 4 |
Baclofen bolus injection |
29 |
Memantine for Spasticity in MS Patients |
Completed |
NCT00638027 |
Phase 4 |
placebo;memantine |
30 |
An International, Multicentre, Prospective, Single-Arm Study to Assess the Effect on Voluntary Movements of AbobotulinumtoxinA 1500 U Administered in Both Upper and Lower Limbs in Conjunction With a Guided Self-Rehabilitation Contract in Adult Subjects With Spastic Hemiparesis |
Completed |
NCT02969356 |
Phase 4 |
|
31 |
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport®) in Comparison With OnabotulinumtoxinA (Botox®) When Treating Adults With Upper Limb Spasticity |
Recruiting |
NCT04936542 |
Phase 4 |
|
32 |
Comparison of the Efficacy of 2 Different Botulinum Toxin Injection Techniques in Gastrocnemius Muscle Spasticity in Hemiplegic Patients: A Randomized Double-blind Controlled Study. |
Not yet recruiting |
NCT05615987 |
Phase 4 |
Onabotulinumtoxina for Injection |
33 |
The Movement of Botulinum Toxin Through the Lateral Gastrocnemius Muscle in Humans: An Expanded Examination |
Terminated |
NCT03367429 |
Phase 4 |
Botox |
34 |
Robotic Rehabilitation and Multimodal Instrumented Assessment of Post-stroke Elbow Motor Functions - a Randomized Controlled Trial Protocol |
Unknown status |
NCT04484571 |
Phase 2, Phase 3 |
|
35 |
Comparison of Clinical Efficacy of Botulinum Neurotoxin Type A1 and A2 for Post-Stroke Lower Limb Spasticity: Phase 2/3 |
Unknown status |
NCT01910363 |
Phase 2, Phase 3 |
A2NTX;BOTOX |
36 |
A Prospective, Open Label, Single Center Study of Patients With Multiple Sclerosis With Lower Extremity Spasticity Who Are Treated With Dysport |
Unknown status |
NCT03585569 |
Phase 3 |
|
37 |
Comparison of Surface Landmark, Ultrasonography and Electric Stimulation Guidance for Botulinum Toxin Injections in Stroke Patients With Spasticity on Upper Extremities. |
Unknown status |
NCT02557737 |
Phase 3 |
Botulinum Toxin Type A |
38 |
Botulinim Toxin Type A Injections by Different Guidance in Stroke Patients With Spasticity on Lower Extremities |
Unknown status |
NCT02469948 |
Phase 3 |
Botulinum toxin type A |
39 |
Randomised Controlled Trial to Evaluate the Effect of a Self-rehabilitation Program in Addition to Usual Treatment for Spasticity (Repeated Botulinum Toxin Injections and Physiotherapy) on Impairment and Activity Limitation in Patients With Spastic Hemiparesis Following Stroke |
Unknown status |
NCT02944929 |
Phase 3 |
|
40 |
Effect of Botulinum Toxin Injections on Motor and Functional Ability of Upper Limb in Adults at Earlier Phases of Spastic Hemiplegia After Stroke |
Unknown status |
NCT00276185 |
Phase 3 |
Time delay treatment of botulinum toxin |
41 |
Central Effects of Botulinum Toxin: Neurophysiological Study in Stroke Patients With Spastic Lower Limb |
Unknown status |
NCT01829763 |
Phase 3 |
injection botox |
42 |
Open-Label, Exploratory Study of the Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP) |
Unknown status |
NCT01343355 |
Phase 2, Phase 3 |
Tamibarotene |
43 |
The Efficacy, Safety and Tolerability of Sativex as an Adjunctive Treatment to Existing Anti-spasticity Medications in Children Aged 8 to 18 Years With Spasticity Due to Cerebral Palsy or Traumatic Central Nervous System Injury Who Have Not Responded Adequately to Their Existing Anti-spasticity Medications: a Parallel Group Randomised, Double-blind, Placebo-controlled Study Followed by a 24-week Open Label Extension Phase |
Completed |
NCT01898520 |
Phase 3 |
Sativex;Placebo |
44 |
A Phase III, Prospective, Multicentre, Open Label, Extension Study, to Assess the Long Term Safety and Efficacy of Repeated Treatment of Dysport® Intramuscular Injection in the Treatment of Lower Limb Spasticity in Adult Subjects With Spastic Hemiparesis Due to Stroke or Traumatic Brain Injury |
Completed |
NCT01251367 |
Phase 3 |
|
45 |
A Two-phase, Phase 3 Study of the Safety and Efficacy of Sativex, in the Symptomatic Relief of Spasticity in Subjects With Spasticity Due to Multiple Sclerosis: Phase A - Single-blind Response Assessment; Phase B - Double-blind, Randomised, Placebo Controlled, Parallel Group Study. |
Completed |
NCT00681538 |
Phase 3 |
Sativex®;Placebo |
46 |
Open-label, Non-controlled, Multicenter Long-term Study to Investigate the Safety and Efficacy of Xeomin® (Incobotulinumtoxin A, NT 201) for the Treatment of Spasticity of the Lower Limb(s) or of Combined Spasticity of Upper and Lower Limb in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy |
Completed |
NCT01905683 |
Phase 3 |
IncobotulinumtoxinA (16-20 Units per kg body weight) |
47 |
Prospective, Multicenter, Randomized, Double-blind, Parallel-group, Dose-response Study of Three Doses Xeomin® (incobotulinumtoxinA, NT 201) for the Treatment of Upper Limb Spasticity Alone or Combined Upper and Lower Limb Spasticity in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy |
Completed |
NCT02002884 |
Phase 3 |
IncobotulinumtoxinA (8 Units per kg body weight);IncobotulinumtoxinA (6 Units per kg body weight);IncobotulinumtoxinA (2 Units per kg body weight) |
48 |
Botulinum Toxin Efficiency on Spasticity of Rectus Femoris and Semitendinosus Muscles as Functional Agonist and Antagonist Muscles. Assessment of Efficiency of Botulinum Toxin on Spasticity in Agonist and Antagonist Muscles Using Clinical Assessment and Gait Analysis in Cerebral Palsy Children: Rectus Femoris and Semitendinosus |
Completed |
NCT00133861 |
Phase 2, Phase 3 |
Botulinum toxin |
49 |
A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis |
Completed |
NCT03290131 |
Phase 3 |
Arbaclofen;Placebo |
50 |
A Randomized, Double-blind, Active Drug Controlled, Multi-Center, Phase I/III Clinical Trial to Evaluate the Efficacy and Safety of CORETOX® in Treatment of Post Stroke Upper Limb Spasticity |
Completed |
NCT03289702 |
Phase 3 |
CORETOX®;BOTOX® |
|